Skip navigation

for Melanoma and other Skin Cancers

Personalized circulating tumor DNA (ctDNA) testing to inform the management of skin cancers.

Inform Early Treatment Decisions


Identify High Risk Patients

Test for presence of MRD after surgery to risk-stratify patients1


Higher risk of recurrence for ctDNA positive patients1


Detect Recurrence Earlier

Detect recurrence prior to standard imaging1

3 months

lead time in detecting recurrence compared to PET/CT1


Predict Response to Treatment

Track changes in ctDNA levels to evaluate treatment response1

6 weeks

To identify patients with poor prognosis due to increasing ctDNA during 1L IO treatment1

Get Started

Inform Your Skin Cancer Treatment Approach With Signatera™

alt text

Explore Signatera data in Skin Cancer

Adjuvant / Surveillance

Use Signatera to inform risk-based adjuvant treatment selection and monitor immunotherapy response

Signatera ctDNA-positive patients had a 10x higher risk of recurrence than ctDNA-negative patients1

Skin Cancer
  • ctDNA-positivity was associated with significantly shorter DMFS (HR=10.77; p=0.01)
  • Outcomes were improved in ctDNA-positive patients who were treated with adjuvant ICI.
  • ctDNA-positivity at week 6 of adjuvant ICI therapy was significantly associated with an inferior DMFS (HR:34.54,P<0.0001)

On-treatment ctDNA dynamics were significantly associated with DMFS1

Skin Cancer
  • Patients who became or remained ctDNA negative experienced superior outcomes than patients who converted to or were persistently ctDNA positive
  • Signatera provided a lead time to recurrence of 3 months vs. standard imaging

* Average time to recurrence by PET/CT: ~9 months vs. average time to recurrence by ctDNA: ~6 months
DMFS = Distant metastasis-free survival; ICI = immune checkpoint inhibitor; MRD =
Molecular residual disease; ctDNA = Circulating tumor DNA


Use Signatera ctDNA dynamics to inform earlier treatment decisions in metastatic melanoma patients

Early on-treatment ctDNA dynamics were predictive of PFS in metastatic melanoma patients receiving 1st line ICI treatment1

At week 6, Signatera identified that patients with increasing ctDNA had a 18x higher risk of progression than ctDNA-negative patients


  • Patients with any increase in ctDNA levels from baseline by week 6 of 1st Line ICI treatment (monotherapy and combination ICIs) had a significantly shorter PFS (HR: 18; p=0.013).
  • Signatera was able to help distinguish between true vs pseudo-progression

Provide Confidence for Patients With Skin Cancer

After Jeffrey started dual immunotherapy for his metastatic melanoma, Signatera™ showed a dramatic drop in his ctDNA levels and helped provide assurance that his treatment was working.

Watch Jeffrey’s story to learn how his oncology team used Signatera™ to help guide his care and restore his confidence in his future.

Is Signatera™ right for your patients with skin cancer?

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.


1Eroglu Z, Krinshpun S, Kalashnikova E, et al. Circulating tumor DNA based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer (2023).

icon-angle icon-bars icon-times